FDA Approves Fayuvi for Sanfilippo Syndrome, Impact on Ultragenyx's Profitability Target
The FDA approved Fayuvi as the first treatment for neurologic manifestations of Sanfilippo syndrome Type A in pediatric patients. This approval adds a new commercial product to Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) portfolio and could significantly impact its path toward profitability by 2027. Ultragenyx reported losses in recent years but expects revenue growth from existing products, with potential additional contributions from Fayuvi. The drug has a high list price of $3.95 million per treatment, positioning it among the world's most expensive drugs. Analysts estimate peak global sales could reach between $200 million and $250 million. The approval reduces regulatory uncertainty but introduces new risks related to commercial uptake and reimbursement. Investor sentiment was mixed before the announcement, with both long and short positions established ahead of the FDA decision.
Tickers: $RARE